Вредност недостатка витамина К или протеина који индукује антагонист-ИИ (ПИВКА) у предвиђању ефикасности транскепатичне артеријске хемоемболизације (ТАЦЕ): ретроспективна студија
PIVKA in transhepatic arterial chemoembolization (TACE)
Sažetak
[Objective]: To investigate the value of AFP combined with degamma-carboxylprothrombin (DCP), vitamin K absence or antagonist-II (PIVKA) in predicting the efficacy of transhepatic arterial chemoembolization (TACE).
[Methods]: The clinical data of 85 patients with hepatocellular carcinoma (HCC) who received TACE at our hospital between October 2021 and March 2023 were retrospectively analyzed. Changes in the serum AFP and DCP levels of patients before TACE and after two consecutive TACE operations were analyzed. The therapeutic effect of TACE was evaluated using the MRECIST criteria. The changes in AFP and DCP levels were compared with the imaging data from the same period (mRECIST criteria). The measurement data were tested for normality, and comparisons between two groups conforming to a normal distribution were performed by two-way independent sample t tests. The Mann‒Whitney U test was used to compare normally distributed data between the two groups. The χ2 test was used to compare the counting data between the two groups, and the Mann‒Whitney U test was used to compare the rank counting data between the two groups. Spearman correlation analysis was used to explore the correlation between mRECIST grade and AFP and DCP levels, and the value of each index in the diagnosis of patients in the remission group was analyzed by subject working characteristic curve analysis.
[Results] According to the mRECIST criteria, 38 patients were in the remission group, and 31 were in the nonremission group. After treatment, the AFP and DCP levels in the remission group were significantly lower than those in the nonremission group (Z = -3.366 and -4.065, P < 0.05). There were statistically significant differences in △AFP, △DCP, △AFP%, and △DCP% between the remission group and the nonremission group (Z = -4.837, -5.597, -4.210, and -5.851, respectively; P < 0.001). The mRECIST stage was negatively correlated with △AFP and △DCP (RS= -0.552 and -0.593, P < 0.001). The area under the working characteristic curve of △AFP% was 0.796, that of △DCP% was 0.912, that of △AFP% + △DCP% combined was 0.921, and that of △AFP% + △DCP% had the greatest diagnostic value.
[Conclusion]: Combined analysis of serum AFP and DCP levels before and after TACE can be used to evaluate the therapeutic effect of TACE in hepatocellular carcinoma patients.
Reference
2.Hiraoka A, Kumada T, Kariyama K, Toyoda H, Yasuda S, Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Ishikawa T, Tada T, Takaguchi K, Itobayashi E, Shimada N, Shibata H, Tanaka T, Tsutsui A, Nagano T, Imai M, Nakamura S, Nouso K. Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. Oncology. 2022;100(2):65-73. doi: 10.1159/000520292. Epub 2021 Nov 29. PMID: 34844247; PMCID: PMC8820430.
3.Wang SY, Su TH, Chen BB, Liu CJ, Liu CH, Yang HC, Tseng TC, Chen PJ, Kao JH. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma. J Formos Med Assoc. 2022 Aug;121(8):1579-1587. doi: 10.1016/j.jfma.2022.01.005. Epub 2022 Jan 22. PMID: 35078686.
4.Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol. 2020 Jan-Feb;10(1):43-80. doi: 10.1016/j.jceh.2019.09.007. Epub 2019 Sep 23. PMID: 32025166; PMCID: PMC6995891.
5.Wang L, Yang X, Wang J, Yu G. Predictive value of PIVKA-II and AFP for the non-objective response of HBV-associated hepatocellular carcinoma after transarterial chemoembolization: a prospective study. Eur J Gastroenterol Hepatol. 2023 Dec 1;35(12):1410-1415. doi: 10.1097/MEG.0000000000002663. Epub 2023 Oct 25. PMID: 37942758.
6.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
7.Sawatsubashi T, Nakatsuka H, Nihei K, Takano T. [A Case of Metachronous Multiple Liver Metastases of AFP and PIVKA-Ⅱ Producing Gastric Cancer, Responding to Transcatheter Arterial Chemoembolization]. Gan To Kagaku Ryoho. 2020 Feb;47(2):319-321. Japanese. PMID: 32381975.
8.Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. JHEP Rep. 2022 Sep 8;4(12):100578. doi: 10.1016/j.jhepr.2022.100578. PMID: 36352896; PMCID: PMC9638834.
9.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
10.Xi D, Xu M, Han M, Guan Q, Guo Q, Yan F, Yao J, Ning Q. Novel Prognostic Nomogram to Predict Progression-Free Survival of Patients with Hepatocellular Carcinoma After Transarterial Chemoembolization. J Hepatocell Carcinoma. 2023 Jun 16;10:909-920. doi: 10.2147/JHC.S412643. PMID: 37346771; PMCID: PMC10281284.
11.Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, Miyata H, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Oncology. 2015;89(3):167-74. doi: 10.1159/000381808. Epub 2015 May 12. PMID: 25999038.
12.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
13.Sun H, Yang W, Zhou W, Zhou C, Liu S, Shi H, Tian W. Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE. Oncol Lett. 2022 Dec 29;25(2):69. doi: 10.3892/ol.2022.13655. PMID: 36644150; PMCID: PMC9827467.
14.Xu R, Ji X, Pei X, Yu Y. Comparison of efficacy and safety between transarterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate and advanced hepatocellular carcinoma. Am J Transl Res. 2023 Feb 15;15(2):1117-1128. PMID: 36915764; PMCID: PMC10006802.
15.Zhao SM, Qiu LW, Zhao H, Gu WW, Yang XH, Gu ZX, Shi RF, Ni CF. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors. J Cancer Res Ther. 2021 Jul;17(3):707-714. doi: 10.4103/jcrt.JCRT_651_20. PMID: 34269303.
16.Kong C, Zhao Z, Chen W, Lv X, Shu G, Ye M, Song J, Ying X, Weng Q, Weng W, Fang S, Chen M, Tu J, Ji J. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. Eur Radiol. 2021 Oct;31(10):7500-7511. doi: 10.1007/s00330-021-07910-0. Epub 2021 Apr 16. PMID: 33860832; PMCID: PMC8452577.
17.Wang S, Zhang X, Chen Q, Jin ZC, Lu J, Guo J. A Novel Neutrophil-to-Lymphocyte Ratio and Sarcopenia Based TACE-Predict Model of Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma. 2023 Apr 20;10:659-671. doi: 10.2147/JHC.S407646. PMID: 37113464; PMCID: PMC10126762.
18.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
19.Kaewdech A, Sripongpun P, Assawasuwannakit S, Wetwittayakhlang P, Jandee S, Chamroonkul N, Piratvisuth T. FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE. Front Med (Lausanne). 2023 May 2;10:1077842. doi: 10.3389/fmed.2023.1077842. PMID: 37200967; PMCID: PMC10185803.
20.Ji Q, Fu Y, Zhu X, Wang L, Ling C. Effect of RFA and TACE combined with postoperative cytokine-induced killer cell immunotherapy in primary hepatocellular carcinoma. J BUON. 2021 Jan-Feb;26(1):235-242. PMID: 33721457.
21.Fan W, Zhu B, Yue S, Zheng X, Yuan G, Yu L, Huang W, Huang S, Wei W, Li F, Huang Z, Tang R, Fan H, Li Z, Qiao L, Huang F, Cheng Y, Zhang Y, Wu Y, Zou X, Xue M, Wang H, Li J. Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study. Eur Radiol. 2023 Apr;33(4):2809-2820. doi: 10.1007/s00330-022-09249-6. Epub 2022 Dec 23. PMID: 36562786; PMCID: PMC10017639.
22.Kong L, Wei G, Lv T, Jiang L, Yang J, Zhao Y, Yang J. Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma. Sci Rep. 2021 Jan 12;11(1):696. doi: 10.1038/s41598-020-80311-3. PMID: 33436856; PMCID: PMC7804028.
23.Liu K, Ding Y, Wang Y, Zhao Q, Yan L, Xie J, Liu Y, Xie Q, Cai W, Bao S, Wang H. Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma. Clin Exp Med. 2023 Jun;23(2):397-409. doi: 10.1007/s10238-022-00810-7. Epub 2022 Mar 28. PMID: 35347503; PMCID: PMC10224837.
24.Chuang YH, Cheng YF, Tsang LL, Ou HY, Hsu HW, Lim WX, Huang PH, Weng CC, Yu CY. Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC. J Hepatocell Carcinoma. 2023 Jan 15;10:81-90. doi: 10.2147/JHC.S398434. PMID: 36685112; PMCID: PMC9850831.
25.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
26.Cao Z, Cheng Y, Wang J, Liu Y, Yang R, Jiang W, Li H, Zhang X. HBP1-mediated transcriptional repression of AFP inhibits hepatoma progression. J Exp Clin Cancer Res. 2021 Apr 1;40(1):118. doi: 10.1186/s13046-021-01881-2. PMID: 33794968; PMCID: PMC8015059.
27.Yang H, Lu L, Guo W, Gong B, Wang X, Chen Y, Chen X. A Longitudinal Study of AFP Trajectories and Clinical Outcomes in Intermediate-Stage Hepatocellular Carcinoma After Hepatectomy. J Hepatocell Carcinoma. 2024 Jan 25;11:219-228. doi: 10.2147/JHC.S432011. PMID: 38293613; PMCID: PMC10825584.
28.Tang X, Zhang Y, Dong X, Jiang G, Hong D, Liu X. The Synergy of Gene Targeting Drug Icaritin Soft Capsule with Immunomodulator and TACE Brings New Hope for Drug Combination in Patients with Advanced Liver Cancer: A Case Report and Literature Review. Cancer Manag Res. 2023 Jul 18;15:707-717. doi: 10.2147/CMAR.S414487. PMID: 37485037; PMCID: PMC10362861.
29.Ma K, Liu J, Wang Y, Zhong Y, Wu Z, Fan R, Guo S. Relationship between plasma cell-free DNA (cfDNA) and prognosis of TACE for primary hepatocellular carcinoma. J Gastrointest Oncol. 2020 Dec;11(6):1350-1363. doi: 10.21037/jgo-20-509. PMID: 33457006; PMCID: PMC7807265.
30.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
31.Song Z, Guo X, Yin C, Wang Y. Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma. Indian J Cancer. 2021 Jan-Mar;58(1):57-61. doi: 10.4103/ijc.IJC_635_18. PMID: 33402587.
32.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
33.Wu Z, Cui L, Qian J, Luo L, Tu S, Cheng F, Yuan L, Zhang W, Lin W, Tang H, Li X, Li H, Zhang Y, Zhu J, Li Y, Xiong Y, Hu Z, Peng P, He Y, Liu L, He K, Shen W. Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China. BMC Cancer. 2023 Apr 7;23(1):325. doi: 10.1186/s12885-023-10802-9. PMID: 37029339; PMCID: PMC10080834.
34.Sun Y, Xiong Y, Wang Q, Qiao W, Zhang H, Zhang Y. Development and validation of a nomogram to predict the recurrence of hepatocellular carcinoma patients with dynamic changes in AFP undergoing locoregional treatments. Front Oncol. 2023 Aug 28;13:1206345. doi: 10.3389/fonc.2023.1206345. PMID: 37700838; PMCID: PMC10494718.
35.Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon. 2024 Mar 28;10(7):e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709.
36.Yao W, Xue M, Lu M, Wang Y, Zhao Y, Wu Y, Fan W, Li J. Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy. Front Oncol. 2020 Dec 17;10:574668. doi: 10.3389/fonc.2020.574668. PMID: 33425729; PMCID: PMC7793644.
37.Yang C, Luo YG, Yang HC, Yao ZH, Li X. Effects of Early TACE Refractoriness on Survival in Patients with Hepatocellular Carcinoma: A Real-World Study. J Hepatocell Carcinoma. 2022 Jul 21;9:621-631. doi: 10.2147/JHC.S373112. PMID: 35903756; PMCID: PMC9317376.
38.Lee M, Shin HP. Efficacy of Transarterial Chemoembolization (TACE) for Early-Stage Hepatocellular Carcinoma. Medicina (Kaunas). 2023 Dec 14;59(12):2174. doi: 10.3390/medicina59122174. PMID: 38138277; PMCID: PMC10744753.
Sva prava zadržana (c) 2025 Qing Shi, Xinxin Ruan, Zhuang Zhang, Jingui Xu
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.